View Item 
      •   R2KN Home
      • Perguruan Tinggi
      • Universitas Gajah Mada
      • Indonesia Journal of Pharmacy
      • View Item
      •   R2KN Home
      • Perguruan Tinggi
      • Universitas Gajah Mada
      • Indonesia Journal of Pharmacy
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin and Aspirin for Stroke Prevention Atrial Fibrillation (SPAF) in the Indonesian healthcare setting

      Date
      2019
      Author
      Dwiprahasto, Iwan; Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, 55281, Indonesia
      Kristin, Erna; Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, 55281, Indonesia
      Endarti, Dwi; Department Pharmaceutics, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, 55281, Indonesia
      Pinzon, Rizaldy Taslim; Clinical Epidemiology & Biostatistics Unit, Faculty of Medicine, Gadjah Mada University Yogyakarta, 55281, Indonesia
      Yasmina, Alfi; Department of Pharmacology, Faculty of Medicine, Lambung Mangkurat University, Banjarmasin, 70123 Indonesia
      Thobari, Jarir At; Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, 55281, Indonesia
      Pratiwi, Woro Rukmi; Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, 55281, Indonesia
      Kartika, Yolanda Dyah; Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, 55281, Indonesia
      Trijayanti, Christiana; Lung Hospital Respira, Jl. Panembahan Senopati No.4, Bantul, Yogyakarta 55713 Yogyakarta, Indonesia
      Metadata
      Show full item record
      Abstract
      Main drugs used in the prevention of stroke among atrial fibrillation (AF) patients are antiplatelets (aspirin) and oral anticoagulants (OAC). OAC therapy can be difficult to administer due to drug and food interactions, adds the burden of required blood monitoring, narrow therapeutic window, and requirements for dose titration. Rivaroxaban is a single-dose oral anticoagulant which does not require blood monitoring, dose titration or has dietary interactions. Phase III clinical data from the ROCKET trial have recently been reported the non-inferiority of rivaroxaban over warfarin for the prevention of strokes in AF patients. To develop an economic model evaluating the clinical and cost-effectiveness of rivaroxaban for the prevention of stroke in non-valvular AF patients in the Indonesian health care settings. We conducted cost effectiveness analysis from the perspective of payer (national health insurance). Effectiveness data used the international data from previous RCT and network metaanalysis studies. Costs data used local data of Indonesia from national health insurance’s reimbursement tariffs. Markov model was used, comprised of health and treatment states describing the management and consequences of AF. The main analysis was based on data from the phase III trials. Three months was used as cycle length. The time horizon was set at patients’ lifetime (20 years). Costs and outcomes were discounted at a 3% annual rate. Subgroup analysis and extensive sensitivity analysis was conducted. Willingness to pay (WTP) threshold in Indonesia was set as 3 times GDP of Indonesia in 2015, equal about IDR 133,375,000 per quality-adjusted life year (QALY). Base case rivaroxaban vs warfarin has ICER of IDR 141,835,063per QALY at the current cost of rivaroxaban IDR 23,500 and ICER of 130,214,687 per QALY at the proposed cost of rivaroxaban IDR 22,000. One-way sensitivity analysis showed that the key drivers of cost-effectiveness were the utility decrement applied to stable warfarin patients, discontinuation/subsequent discontinuation rates for rivaroxaban, and discontinuation/subsequent discontinuation rates for warfarin. The probabilistic sensitivity analysis suggested that rivaroxaban was cost-effective compared to warfarin in about 45% of cases at the WTP per QALY. Rivaroxaban with the proposed price of IDR 22,000 was considered to be more cost-effective when compared to warfarin.
      URI
      http://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/article/view/1507/896 http://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/article/view/1507
      Collections
      • Indonesia Journal of Pharmacy [413]

      Related items

      Showing items related by title, author, creator and subject.

      • HEPATOPROTECTIVE EFFECT OF GAMAVUTON-0 AGAINST D˗GALACTOSAMINE/LIPOPOLYSACCHARIDE-INDUCED FULMINANT HEPATIC FAILURE 

        Nurrochmad, Arief; Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara Yogyakarta 55281, Indonesia; Sari, Ika Puspita; Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara Yogyakarta 55281, Indonesia; Murwanti, Retno; Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara Yogyakarta 55281, Indonesia; ., Sardjiman; Curcumin Research Center, Faculty of Pharmacy, Universitas Gadjah Mada Yogyakarta 55281, Indonesia.; Candraningrum, Triana; Curcumin Research Center, Faculty of Pharmacy, Universitas Gadjah Mada Yogyakarta 55281, Indonesia.; Afritasari, Dyah; Curcumin Research Center, Faculty of Pharmacy, Universitas Gadjah Mada Yogyakarta 55281, Indonesia.; Martina, Devina; Curcumin Research Center, Faculty of Pharmacy, Universitas Gadjah Mada Yogyakarta 55281, Indonesia.; Siahaan, Iren Wati; Curcumin Research Center, Faculty of Pharmacy, Universitas Gadjah Mada Yogyakarta 55281, Indonesia.
      • Formulation of Insulin Self Nanoemulsifying Drug Delivery System and Its In Vitro-In Vivo Study 

        Winarti, Lina; Department of Pharmaceutics, Jember University, Indonesia; Suwaldi, Suwaldi; Dept of Pharmaceutical Technology Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia; Martien, Ronny; Dept of Pharmaceutical Technology Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia; Hakim, Lukman; Dept of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.
      • Effects of Antioxidant, Anti-Collagenase, Anti-Elastase, Anti-Tyrosinase of The Extract and Fraction From Turbinaria decurrens Bory. 

        Nurrochmad, Arief; Dept of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara Yogyakarta 55281, Indonesia; Wirasti, Wirasti; Post Graduate Student of Faculty of Pharmacy Universitas Gadjah Mada; Dirman, Arifin; Post Graduate Student of Faculty of Pharmacy Universitas Gadjah Mada; Lukitaningsih, Endang; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara Yogyakarta 55281, Indonesia; Rahmawati, Adillah; Post Graduate Student of Faculty of Pharmacy Universitas Gadjah Mada; Fakhrudin, Nanang; Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara Yogyakarta

      Copyright © Badan Litbangkes - Kementerian Kesehatan RI
      Jl. Percetakan Negara no.29, Jakarta Pusat 10560, Indonesia
      All rights reserved. 2019
      Contact Us | Send Feedback
        

       

      Browse

      All of R2KNCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

      My Account

      LoginRegister

      Copyright © Badan Litbangkes - Kementerian Kesehatan RI
      Jl. Percetakan Negara no.29, Jakarta Pusat 10560, Indonesia
      All rights reserved. 2019
      Contact Us | Send Feedback